Table 2.
Published clinical studies on PARP inhibitors combined with radiotherapy.
| Treatments | Cancer | Phase | Efficacy | Identifier |
|---|---|---|---|---|
| Veliparib + RT | Breast cancer | I | 3-year OS 56.6%, PFS 50% | NCT01477489 |
| Veliparib + Capecitabine + RT | Rectal cancer | I | Tumor downstaging after surgery-71%; pCR 29% | NCT01589419 |
| Veliparib + RT | Gliomas | I/II | Phase I: PR 0% SD 91.7% PD 8.3% Phase II: PR 13.2% SD 71.7% PD 9.4% |
NCT01514201 |
| RT + Temozolomide +/− Veliparib | Glioblastoma | II | Without veliparib PFS at 6 months 31% Median OS:12.8 months With veliparib PFS at 6 months 46% Median OS:12.7 months |
NCT02152982 |
| Olaparib + RT + Cetuximab | HNSCCs | I | Median OS: 37 months 2-year OS (72%), PFS (63%) |
NCT02308072 |
HNSCCs, head and neck squamous cell carcinoma; OS, overall survival; pCR, pathological complete response; PD, progressive disease; PFS, progression free survival; PR, partial response; RT, radiotherapy; SD, stable disease.